Through blocking the activation of PPARγ via the PPARγ‐specific antagonist SR202, the impact of OA‐rich EN on remodeling the M1/M2 polarization balance and alleviating the symptoms of IBD was reversed. The gene discussed is PPARG; the disease is inflammatory bowel disease.